Warning: The NCBI web site requires JavaScript to function. more...
Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance.
Marfurt J, Smith TA, Hastings IM, Müller I, Sie A, Oa O, Baisor M, Reeder JC, Beck HP, Genton B.
Malar J. 2010 Jan 7;9:8.
Related citations
The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea.
Marfurt J, Müller I, Sie A, Oa O, Reeder JC, Smith TA, Beck HP, Genton B.
Malar J. 2008 Apr 19;7:61.
Markers of anti-malarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolates.
Dlamini SV, Beshir K, Sutherland CJ.
Malar J. 2010 Mar 3;9:68.
Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications.
Mubjer RA, Adeel AA, Chance ML, Hassan AA.
Malar J. 2011 Aug 21;10:245.
Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali.
Tekete M, Djimde AA, Beavogui AH, Maiga H, Sagara I, Fofana B, Ouologuem D, Dama S, Kone A, Dembele D, Wele M, Dicko A, Doumbo OK.
Malar J. 2009 Feb 26;8:34.
Monitoring of malaria parasite resistance to chloroquine and sulphadoxine-pyrimethamine in the Solomon Islands by DNA microarray technology.
Ballif M, Hii J, Marfurt J, Crameri A, Fafale A, Felger I, Beck HP, Genton B.
Malar J. 2010 Oct 6;9:270.
Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique.
Enosse S, Magnussen P, Abacassamo F, Gómez-Olivé X, Rønn AM, Thompson R, Alifrangis M.
Malar J. 2008 Jul 1;7:115.
Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy.
Mbacham WF, Evehe MS, Netongo PM, Ateh IA, Mimche PN, Ajua A, Nji AM, Irenee D, Echouffo-Tcheugui JB, Tawe B, Hallett R, Roper C, Targett G, Greenwood B.
Malar J. 2010 Jan 27;9:34.
Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea.
Genton B, Baea K, Lorry K, Ginny M, Wines B, Alpers MP.
P N G Med J. 2005 Sep-Dec;48(3-4):141-50.
Mutations in PFCRT K76T do not correlate with sulfadoxine-pyrimethamine-amodiaquine failure in Pikine, Senegal.
Sarr O, Ahouidi AD, Ly O, Daily JP, Ndiaye D, Ndir O, Mboup S, Wirth DF.
Parasitol Res. 2008 Sep;103(4):765-9. Epub 2008 Jun 5.
Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia.
Mula P, Fernández-Martínez A, de Lucio A, Ramos JM, Reyes F, González V, Benito A, Berzosa P.
Malar J. 2011 Aug 2;10:214.
Drug resistance in Plasmodium falciparum from the Chittagong Hill Tracts, Bangladesh.
van den Broek IV, van der Wardt S, Talukder L, Chakma S, Brockman A, Nair S, Anderson TC.
Trop Med Int Health. 2004 Jun;9(6):680-7.
Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea.
Marfurt J, Müeller I, Sie A, Maku P, Goroti M, Reeder JC, Beck HP, Genton B.
Am J Trop Med Hyg. 2007 Nov;77(5):947-54.
Dynamics of pfcrt alleles CVMNK and CVIET in chloroquine-treated Sudanese patients infected with Plasmodium falciparum.
Gadalla NB, Elzaki SE, Mukhtar E, Warhurst DC, El-Sayed B, Sutherland CJ.
Malar J. 2010 Mar 12;9:74.
Prevalence of mutations associated with antimalarial drugs in Plasmodium falciparum isolates prior to the introduction of sulphadoxine-pyrimethamine as first-line treatment in Iran.
Zakeri S, Afsharpad M, Raeisi A, Djadid ND.
Malar J. 2007 Nov 13;6:148.
Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré.
Bonnet M, Roper C, Félix M, Coulibaly L, Kankolongo GM, Guthmann JP.
Malar J. 2007 May 3;6:54.
A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance.
Carnevale EP, Kouri D, DaRe JT, McNamara DT, Mueller I, Zimmerman PA.
J Clin Microbiol. 2007 Mar;45(3):752-61. Epub 2006 Nov 22.
High chloroquine treatment failure rates and predominance of mutant genotypes associated with chloroquine and antifolate resistance among falciparum malaria patients from the island of Car Nicobar, India.
Das MK, Lumb V, Mittra P, Singh SS, Dash AP, Sharma YD.
J Antimicrob Chemother. 2010 Jun;65(6):1258-61. Epub 2010 Apr 2.
Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance.
Francis D, Nsobya SL, Talisuna A, Yeka A, Kamya MR, Machekano R, Dokomajilar C, Rosenthal PJ, Dorsey G.
J Infect Dis. 2006 Apr 1;193(7):978-86. Epub 2006 Mar 1.
Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, Mwita A, Nkya W, Kataraihya J, Abdulla S, Beck HP, Mshinda H.
Am J Trop Med Hyg. 2004 Dec;71(6):696-702.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on